The primary immunological function of HLA class I molecules appears to be the binding and presentation of peptides to T-cell receptors. Soluble class I molecules, like class II major histocompatibility complex (MHC) molecules (1) (2) (3) (4) (5) , have been shown to be capable of directly binding synthetic peptides (6) (7) (8) . The putative peptide binding site of class I molecules is bounded by two a-helices (one from the al and one from the a2 domain) with a p-pleated sheet floor (9, 10) .
The proper folding and assembly of class I heavy chains with ,82-microglobulin may actually require the presence of a bound peptide in this site (11) .
Although it seems reasonable to assume that class I molecules must be able to bind a wide array of peptides to cover the universe of antigens which they must present to T-cell receptors, there is currently very little information on the size of the peptide repertoire that any particular class I molecule can bind, and the number of HLA alleles to which any given peptide can bind. In a previous study (12) , we assessed the specificity of peptide binding by the HLA-A2.1 molecule by analyzing the ability of a panel of synthetic peptides derived from the sequences of a diverse group of proteins to functionally compete for presentation of the influenza virus matrix protein (Ml) peptide 55-73 to peptide-specific cytotoxic T lymphocyte (CTL) lines. The results demonstrated that 25% of these unrelated peptides could compete for M1-(55-73) presentation, indicating that the HLA-A2.1 molecule can bind a clearly limited, but broad spectrum of peptides.
To determine the extent to which these findings with the HLA-A2.1 molecule might be generalizable, we have performed a similar analysis on the specificity of peptide binding by the HLA-B37 molecule. McMichael et al. (13) 10 ,ug/ml for 3 hr at 37'C] plus rIL-2 added at 5 units/ml 24 hr later. The HLA-A2.1-restricted Ml-(55-73)-peptide-specific CTL line 17B5.C2 was described previously (21) . CTL activity was measured in a standard 4-to 5-hr 51Cr-release assay as described previously (12) , using B-cell targets that were either infected with influenza virus or incubated with synthetic peptides. Competitive peptide inhibition assays were performed as described (12) (Table 1 ) was chosen at random from a collection of peptides that had been made for studies unrelated to the present investigation and that was previously used to study the specificity of peptide binding by HLA-A2.1 (12) . Ten of these peptides had been previously shown to be recognized in association with MHC molecules (Table 1) . A representative experiment that utilizes 8 of the 26 synthetic peptides in Table 1 Comparison of HLA-B37-and HLA-A2.1-Binding Peptides. Our previous study (12) demonstrated that six of the peptides in Table 1 could bind to HLA-A2.1 as determined by target cell sensitization and recognition by CTL (nos. 13, 27) or by inhibition of Ml peptide presentation by HLA-A2.1 (nos. 14, 23, 24, 25, and 26). None of these six HLA-A2.1-binding peptides were scored as positive for inhibition of HLA-B37 presentation (Fig. 3B) . Similarly, none, of the peptides that were scored as positive for inhibition of HLA-B37 presentation (nos. 2-12) were scored as positive for inhibition of HLA-A2.1 presentation (Fig. 3B) sentation of M1-(55-73) peptide to Mi-peptide-specific CTL (12) . The reciprocal experiment of using the M1-(55-73) peptide to inhibit presentation of NP-(335-350) by HLA-B37 was also performed. The results (Fig. 4) demonstrate that the NP-(335-350) peptide (no. 1) could inhibit presentation of the Ml peptide (no. 27) by HLA-A2.1 to an Mi-peptide-specific CTL line to an extent greater than the inhibition produced by the positive control competitor peptide S61 (Fig. 4 A and B) . On the other hand, the Ml peptide could not inhibit presentation of the NP-(335-350) peptide by HLA-B37 to a NPpeptide-specific CTL line (Fig. 4 C and D 
DISCUSSION
The results presented in this and a previous report (12) demonstrate that there are clear differences in the peptides that can compete for presentation of antigenic peptides by HLA-B37 and HLA-A2.1. The different patterns of peptide binding by these two class I molecules are apparently not due to differences in their capacities to bind and present the antigenic peptides, since in both systems the antigenic peptides were used at equal molar concentrations (0.2 MtM). The observed differences in peptide competition between HLA-B37 and HLA-A2.1 most likely represent real differences in the specificity of their peptide binding sites (9, 10 (24) , it may suggest that these two loci have evolved to provide different peptide-binding specificities. The existence of A-ness and B-ness in the nucleotide sequences of HLA-A and -B genes (25) is also indicative of a functional diversification of these loci.
The structural basis for the observed differences in peptide binding specificity of HLA-B37 and HLA-A2.1 can be analyzed by comparison of the amino acid sequences of HLA-A2.1 (26) and HLA-B37 (27) . These two class I molecules differ in their al and a2 domains at 32 amino acid positions, 13 of which point into the peptide-binding site and are available for ligand binding (10 [28] [29] [30] . Thus, these residues might also be involved in peptide selection by HLA-B37. In addition, HLA-A2.1 and HLA-B37 also differ at residues 24, 45 and 67, which are located in the "45 pocket" (31, 32) , a cavity that extends from the peptide-binding groove and is postulated to be capable of influencing peptide binding (31, 32 
